AstraZeneca PLC’s (AZN) breast cancer drug Faslodex doesn’t represent value for money and consequently shouldn’t be made available on the U.K.'s publicly funded National Health Service, according to the country’s medical cost-effectiveness body, the National Institute for Health and Clinical Excellence. NICE said its independent appraisal committee decided not to back Faslodex, also known as fulvestrant, as an alternative to aromatase inhibitor therapy in postmenopausal women who have locally advanced or metastatic breast cancer that is estrogen-receptor-positive.
